August 1, 2025

The Efficiency and Safety of Low-Dose Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonate

View Full Paper

Ask AI

Bookmark

Authors

WHWasana HongkanChonburi Hospital NPNarueporn PetarwutChonburi Hospital TSThanatda SiripornChonburi Hospital

Discussion

Member takes

Implication

Randomized trial compared low-dose indomethacin with standard dosing for PDA closure in preterm neonates, indicating similar effectiveness and safety.

Key Points

MAIN FINDING: Low-dose intravenous indomethacin shows similar efficacy for closure of patent ductus arteriosus in preterm neonates compared to standard dosing.
KEY EVIDENCE: Both low-dose (2 doses) and conventional (3 doses) regimens showed no significant differences in PDA closure rates at 72 hours and 7 days.
APPROACH: A randomized, controlled non-inferiority trial involved 128 preterm neonates with significant PDA, comparing two dosing protocols.
SIGNIFICANCE: Findings support the use of lower-dose indomethacin as a safe and effective alternative, potentially reducing medication exposure in vulnerable neonates.

Cite This Study

Hongkan et al. (2025) studied this question.

synapsesocial.com/papers/689a0c6be6551bb0af8cfd58 https://doi.org/10.21203/rs.3.rs-7084021/v1

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial compared low-dose indomethacin with standard dosing for PDA closure in preterm neonates, indicating similar effectiveness and safety.

The Efficiency and Safety of Low-Dose Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonate

Discussion

Member takes

Implication

Key Points

Cite This Study

The Efficiency and Safety of Low-Dose Intravenous Indomethacin for Closure of Patent Ductus Arteriosus in Preterm Neonate

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider